REL proto-oncogene
RELgeneREL is an NF-κB family member driving post-MI T cell and immune activation.
Pathway placement
Cascade stepPlaque inflammation
Confidencehigh
RationaleNF-κB family transcription factor; post-MI immune activation.
Druggability
DruggableNo
Known drugs / candidates0
Small-molecule tractableNo
Antibody tractableNo
EnsemblENSG00000162924
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I49
C — confounder / Type-II72
A — assay feasibility52
E — evidence strength27
T1DI (composite)6
Specificity differential (R−C)-22.6
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Whole blood — gene is not a circulating analyte; measure protein product or genotype
Collection tube
K2-EDTA whole blood (lavender-top)
Method / principle
SNP genotyping / sequencing; or immunoassay of encoded protein
Reagent / substrate
Allele-specific primers/probes (TaqMan) or NGS panel; or antibody for protein
Platform
qPCR / NGS / array
Turnaround · availability
Send-out · Genotyping widely available; protein assay variable
Literature evidence(1)
- Persistent transcriptional changes in cardiac adaptive immune cells following myocardial infarction: New evidence from the re-analysis of publicly available single cell and nuclei RNA-sequencing data sets.Journal of molecular and cellular cardiology · 2024 · PMID 38734060 · doi